<- Go home

Added to YB: 2024-12-26

Pitch date: 2024-12-22

TMDX [bullish]

TransMedics Group, Inc.

+100.21%

current return

Author Info

A team of 15-year-olds who share long, short, and quant trading ideas. Sign up for the newsletter.

Company Info

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

Market Cap

$4.5B

Pitch Price

$63.33

Price Target

N/A

Dividend

N/A

EV/EBITDA

35.52

P/E

51.63

EV/Sales

7.99

Sector

Health Care Equipment and Supplies

Category

growth

Show full summary:
LONG TMDX: A Growth Company Down 40% Due to Temporary Problems Misinterpreted as Permanent Growth Deceleration

TMDX: OCS tech leader in organ transport, 300% 5yr stock surge. Q3 rev dip due to fleet maintenance. Record Q4 flights signal market share gains despite low transplant volumes. Valuation at 7.2x TTM sales justified by growth potential, market leadership. Risks: fleet issues, prolonged volume decline. Catalysts: earnings, volume recovery, end of tax-loss selling.

Read full article (6 min)